Table 4.
Linear Regressions With Baseline MetS Components Predicting 10-Year Changes in mtDNAcn and TL (n = 989)
| Baseline Predictors (per SD Increase) | 10-y Δ mtDNAcn |
10-y Δ TL |
||||
|---|---|---|---|---|---|---|
| B | SE | P | B | SE | P | |
| Waist circumference (per 13.8 cm) | −7.23 | 3.71 | 0.05 | −3.02 | 7.77 | 0.70 |
| Triglycerides (per 1.21 mmol/L) | −4.02 | 3.50 | 0.25 | −1.27 | 7.27 | 0.86 |
| HDL cholesterol (per 0.36 mmol/L) | 7.18 | 3.83 | 0.06 | 3.58 | 7.99 | 0.65 |
| Systolic BP (per 13.7 mm Hg) | −2.23 | 3.68 | 0.54 | 3.45 | 7.67 | 0.65 |
| Fasting glucose (per 0.72 mmol/L) | −13.29 | 3.98 | 0.001 | −1.33 | 8.34 | 0.87 |
| Number of metabolic dysregulationsa | −7.72 | 3.19 | 0.02 | −0.07 | 6.66 | 0.99 |
| MetS diagnosisb | −28.86 | 10.41 | 0.006 | −0.81 | 21.79 | 0.97 |
Adjusted for age, sex, education, race, smoking, alcohol, physical activity, and baseline cellular aging marker.
a
Metabolic dysregulations defined as waist circumference >102 cm (men) or >88 cm (women); triglycerides >1.7 mmol/L; HDL cholesterol <1.03 mmol/L (men) or <1.30 mmol/L (women); systolic BP >130 or diastolic >85 mm Hg or antihypertensives; fasting plasma glucose >6.1 mmol/L or antidiabetic medication.
b
MetS defined as ≥3 dysregulations.